Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia

Urology

Volumn 55, Issue 4, 2000, Pages 533-539

  Boyle, Peter ^d   Robertson, Chris ^a   Lowe, Franklin ^b   Roehrborn, Claus ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SABAL EXTRACT;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; URINE FLOW RATE;

ANDROGEN ANTAGONISTS; HUMANS; MALE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; SERENOA; TREATMENT OUTCOME; URODYNAMICS;

EID: 0034058050     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00593-2     Document Type: Article

References (37)

1. Oishi K., Boyle P., Barry M.J., et al. Epidemiology and natural history of BPH. Denis L., Murphy G., Khoury S. Third International Consultation on BPH. 1998;Scientific Communications International, Jersey.
2. Neal D.E. Watchful waiting or drug therapy for benign prostatic hyperplasia? Lancet. 2:1997;305-306.
3. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride meta-analysis of randomized clinical trials . Urology. 48:1996;398-405.
4. Levy J.B., Ramchandani P., Berlin J.W., et al. Vesicourethral healing following radical prostatectomy is it related to surgical approach? Urology. 44:1994;888-892.
5. Di Salle E., Briatico G., Giudici D., et al. Novel aromatase and 5 alpha-reductase inhibitors. J Steroid Biochem Mol Biol. 49:1994;289-294.
6. Di Salle E., Briatico G., Giudici D., et al. Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073). J Steroid Biochem Mol Biol. 48:1994;241-248.
7. Jardin A., Bensadoun H., Delauche-Cavallier M.C., et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet. 337:1991;1457-1461.
8. Abrams P. Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies. Eur Urol. 32:1997;39-46.
9. Buck A.C. Phytotherapy for the prostate. Br J Urol. 78:1996;325-336.
10. Plosker G.L., Brogden R.N. Serenoa repens (Permixon) a review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia . Drugs Aging. 9:1996;379-395.
11. Lowe F.C., Ku J.C. Phytotherapy in treatment of benign prostatic hyperplasia a critical review . Urology. 48:1996;12-20.
12. Iehlé C., Délos S., Guirou O., et al. Human prostatic steroid 5α-reductase isoforms a comparative study of selective inhibitors . J Steroid Biochem Mol Biol. 48:1995;347-352.
13. Délos S., Iehlé C., Martin P.M., et al. Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol. 48:1994;347-352.
14. Délos S., Carsol J.L., Ghazarossian E., et al. Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. J Steroid Biochem Mol Biol. 55:1995;375-383.
15. Paubert-Braquet M., Cousse H., Raynaud J.P., et al. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol. 33:1998;340-347.
16. Bayne C., Donnelly F., Ross M., et al. Serenoa repens (Permixon®) a 5α-reductase type I and II inhibitor: new evidence in a co-culture model of BPH . Prostate. 40:1999;232-241.
17. Di Silverio F., Monti S., Sciarra A., et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate. 37:1998;77-83.
18. Ragab A., Ragab-Thomas J.M.F., Delhon A., et al. Effects of Permixon® (Sereprostat® in Spain) on phospholipase A2 activity and on arachidonic acid metabolism in cultured prostatic cells. Di Silverio F., Steg A. New Trends in Bladder Cancer Chemotherapy - New Trends in BPH Etiopathogenesis. Proceedings of the International Workshop in Urology, July 22-25, 1987, Cannes. 1988;293-296 Acta Medica, Rome.
19. Paubert-Braquet M., Mencia H.J., Cousse H., et al. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 57:1997;299-304.
20. Descotes J.L., Rambeaud J.J., Deschaseaux P., et al. Placebo controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest. 9:1995;291-297.
21. Champault G., Patel J.C., Bonnard A.M. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol. 18:1984;461-462.
22. Cukier J., Ducasso J., Le Guillou M., et al. Permixon® versu placebo. Résultats d'une étude multicentrique. C R Ther Pharmacol Clin. 4:1999;15-21.
23. Emili E., Lo Cingo M., Petrone U. Risulti clinici su un nuovo farmaco nella terapia dell'ipertrofia della prostata (Permixon®). Urologia. 50:1983;1042-1049.
24. Tasca A., Barulli M., Cavvazzana A., et al. Treatment of obstruction in prostatic adenoma using extract of Serenoa repens. Double blind clinical test v. placebo. Minerva Urol Nefrol. 37:1985;87-91.
25. Boccafoschi C., Annoscia S. Comparison of Serenoa repens extract and placebo in controlled clinical trial in patients with prostatic adenomatosis. Urologia. 50:1983;1-14.
26. Reece S.H., Memon A., Smart C.J., et al. The value of Permixon in benign prostatic hypertrophy. Br J Urol. 58:1986;36-40.
27. Carraro J.C., Raynaud J.P., Koch G., et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia a randomized international study of 1,098 patients . Prostate. 29:1996;231-240.
28. Grasso M., Montesano A., Buonaguidi A., et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol. 48:1995;97-103.
29. Adriazola Semino M., Lozano O.J., Garcia C.E., et al. Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and Serenoa repens. Arch Esp Urol. 45:1992;211-213.
30. Mandressi A., Tarallo U., Maggioni A., et al. Terapia medica dell'adenoma prostatico confronto della efficacia dell etratto si Serenoa repens (Permixon®) versus l'estratto di Pygeum africanum e placebo . Urologia. 50:1983;752-758.
31. Foroutan F. Wirksamkeit und Vertraglichkeit von Permixon® bei einem grosseren Patientenkollektiv (592 Patienten) unter Praxisbedingungen. J Urol Urogynakol. 2:1997;17-21.
32. Authié D., Cauquil J. Appréciation de l'efficacité de Permixon® en pratique quotidienne. C R Ther Pharmacol Clin. 56:1987;4-13.
33. Stram D.O. Meta analysis of published data using a linear mixed effects model. Biometrics. 52:1996;536-544.
34. Bryk A.S., Raudenbush S.W. Hierarchical Linear Models. 1992;Sage Publications, London.
35. Woodhouse G, Rasbash J, Goldstein H, et al: MLn Command Reference. London, Multilevel Models Project, Institute of Education, 1995.
36. Denis L, Griffiths K, Khoury S, et al (Eds): Fourth International Consultation on BPH. Plymouth: Health Publications Ltd, 1998.
37. Wilt T.J., Ishani A., Stark G., et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia a systematic review . JAMA. 280:1998;1604-1609.